ARTICLE | Company News

Celenex takeout first of several expected Amicus gene therapy deals

September 21, 2018 4:34 PM UTC

Just weeks after gaining its first FDA approval, Amicus Therapeutics Inc. (NASDAQ:FOLD) has announced its entrance into the gene therapy space with the acquisition of Nationwide Children's Hospital spinout Celenex (Columbus, Ohio) for $100 million in cash up front, plus milestones.

More deals are on the way, Chairman and CEO John Crowley said on a conference call Sept. 20 to discuss the deal, with Amicus planning to in-license additional gene therapies in the coming months...